China Pharma Holdings Inc Dossier - Source-backed chat

China Pharma Holdings Inc

CPHINYSE

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.65Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $28.1M

Enterprise Value $31.6M

Shares Outstanding 40.5M diluted

Next Earnings Date14 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

China Pharma Holdings, Inc. (CPHI) faces severe operational and financial distress, characterized by a persistent net loss, a substantial working capital deficit of $5.3 million, and extremely limited cash reserves of $0.17 million as of March 31, 2026. The company's survival is heavily dependent on related-party loans from its Chairperson and her spouse, leading management to issue a formal going concern warning. While the company is attempting to pivot toward specialized medical devices (such as its Dry Eye Disease therapeutic device) and has expanded its patent portfolio through highly dilutive share issuances, near-term liquidity pressures and intense competition from China's centralized drug procurement system present overwhelming risks to equity holders.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0525%

The company fails to secure additional financing or related-party loans, leading to an inability to continue as a going concern. Delisting from the NYSE American occurs due to failure to meet continued listing standards, and the company is forced into restructuring or liquidation, resulting in near-total loss of value for common shareholders.

Base CaseCentral scenario

$0.5060%

China Pharma continues to operate under severe liquidity constraints, relying on periodic related-party funding to survive. Revenue remains stagnant or declines due to centralized procurement pressures on its generic drug portfolio. The company faces ongoing risks of dilution from equity offerings or patent acquisitions, and the stock trades at depressed levels with high volatility.

Bull CaseUpside scenario

$1.5015%

The company successfully commercializes its patented Dry Eye Disease therapeutic device in China, capturing a meaningful share of the projected $579.51 million market by 2030. Concurrently, newly acquired drug patents generate high-margin revenue streams, allowing the company to achieve operating profitability, eliminate its working capital deficit, and regain compliance with NYSE American listing standards without further diluting shareholders.

Scenarios reflect our research view at the research date.

Key Investment Merits

Diverse portfolio of 22 approved generic drug products targeting high-incidence therapeutic areas such as cardiovascular, CNS, and infectious diseases.
Strategic pivot toward specialized medical devices, including a patented Dry Eye Disease therapeutic device targeting a large addressable market in China.
Substantial net operating loss (NOL) carryforwards in China of approximately $31.2 million available through 2030 to offset future taxable income.

Key Investment Risks

Substantial doubt about the company's ability to continue as a going concern due to severe working capital deficit and minimal cash reserves.
Intense pricing pressure and loss of market share resulting from China's centralized volume-based drug procurement system.
Severe shareholder dilution, as evidenced by the issuance of 25 million shares (representing a massive increase in shares outstanding) in Q1 2026 to acquire patents.
High dependence on related-party loans from the Chairperson and her spouse to fund basic operations.

Thesis Invalidation Triggers

Failure of the Chairperson or her spouse to extend or renew related-party loans.
Rejection or significant delay of NMPA approval for the Dry Eye Disease therapeutic device.
Delisting notification from the NYSE American due to failure to maintain minimum stockholders' equity or share price requirements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.